ArticleOncology letters2026
TIMP1 expression in colorectal cancer: Linking prognosis, tumor immunity and molecular pathways.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) is highly expressed in several cancer types, including lung, brain, prostate, breast and colon cancer, and is associated with a poor prognosis. However, further comprehensive research is required. The present study aimed to explore TIMP1 expression in colorectal cancer (CRC), its prognostic relationship and its connection to tumor immunity, using data from The Cancer Genome Atlas database and clinical samples. The present study evaluated the correlation between TIMP1 expression and CRC by integrating RNA sequencing data, and clinical information from The Cancer Genome Atlas (TCGA), UALCAN and GEPIA2 databases, as well as clinical samples. The findings demonstrated that TIMP1 is highly expressed in CRC tissues and is associated with a poor prognosis. Notably, high TIMP1 levels in CRC were positively correlated with the numbers of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.